Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs >

Titan Pharmaceuticals Inc. (TTNP)

Add TTNP Price Alert      Hide Sticky   Hide Intro
Moderator: TRUTH
Search This Board: 
Last Post: 10/23/2017 2:00:00 PM - Followers: 191 - Board type: Free - Posts Today: 6

Titan Pharmaceuticals, Inc.
                                                                                                                           Click For New and Improved Website

                                                                                                                                   Probuphine Logo

                  5/26/2016-FDA Approves First Buprenorphine Implant For Treatment Of Opioid Dependence
                                             Expanded use and availability of medication-assisted treatment is a top priority of federal effort to combat opioid epidemic

                                                              Probuphine Healthcare Provider Locator



The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.

Until today, buprenorphine for the treatment of opioid dependence was only approved as a pill or a film placed under the tongue or on the inside of a person’s cheek until it dissolved. While effective, a pill or film may be lost, forgotten or stolen. However, as an implant, Probuphine provides a new treatment option for people in recovery who may value the unique benefits of a six-month implant compared to other forms of buprenorphine, such as the possibility of improved patient convenience from not needing to take medication on a daily basis. An independent FDA advisory committee supported the approval of Probuphine in a meeting held earlier this year.

"Opioid abuse and addiction have taken a devastating toll on American families. We must do everything we can to make new, innovative treatment options available that can help patients regain control over their lives,” said FDA Commissioner Robert M. Califf, M.D. “Today’s approval provides the first-ever implantable option to support patients’ efforts to maintain treatment as part of their overall recovery program.”

Expanding the use and availability of medication-assisted treatment (MAT) options like buprenorphine is an important component of the FDA’s opioid action plan and one of three top priorities for the U.S. Department of Health and Human Services’ Opioid Initiative aimed at reducing prescription opioid and heroin related overdose, death and dependence.

Opioid dependence is the diagnostic term used for the more common concept, “addiction,” in the Probuphine clinical trials. Addiction is defined as a cluster of behavioral, cognitive and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use, persisting in drug use despite harmful consequences, a higher priority given to drug use than to other activities and obligations, as well as the possibility of the development of tolerance or development of physical dependence. Physical dependence is not the same as addiction. Newer diagnostic terminology uses the term “opioid use disorder,” which includes both milder forms of problematic opioid use as well as addiction.

MAT is a comprehensive approach that combines approved medications (currently, methadone, buprenorphine or naltrexone) with counseling and other behavioral therapies to treat patients with opioid use disorder. Regular adherence to MAT with buprenorphine reduces opioid withdrawal symptoms and the desire to use, without causing the cycle of highs and lows associated with opioid misuse or abuse. At sufficient doses, it also decreases the pleasurable effects of other opioids, making continued opioid abuse less attractive. According to the Substance Abuse and Mental Health Services Administration, patients receiving MAT for their opioid use disorder cut their risk of death from all causes in half.

“Scientific evidence suggests that maintenance treatment with these medications in the context of behavioral treatment and recovery support are more effective in the treatment of opioid use disorder than short-term detoxification programs aimed at abstinence,” said Nora Volkow, M.D., director of the National Institute on Drug Abuse at the National Institutes of Health. “This product will expand the treatment alternatives available to people suffering from an opioid use disorder.”

Probuphine should be used as part of a complete treatment program that includes counseling and psychosocial support. Probuphine consists of four, one-inch-long rods that are implanted under the skin on the inside of the upper arm and provide treatment for six months. Administering Probuphine requires specific training because it must be surgically inserted and removed. Only a health care provider who has completed the training and become certified through a restricted program called the Probuphine Risk Evaluation and Mitigation Strategy (REMS) program should insert and remove the implants. If further treatment is needed, new implants may be inserted in the opposite arm for one additional course of treatment. The FDA is requiring postmarketing studies to establish the safety and feasibility of placing the Probuphine implants for additional courses of treatment.

The safety and efficacy of Probuphine were demonstrated in a randomized clinical trial of adults who met the clinical criteria for opioid dependence and were considered stable after prior buprenorphine treatment. A response to MAT was measured by urine screening and self-reporting of illicit opioid use during the six month treatment period. Sixty-three percent of Probuphine-treated patients had no evidence of illicit opioid use throughout the six months of treatment – similar to the 64 percent of those who responded to sublingual (under the tongue) buprenorphine alone.

The most common side effects from treatment with Probuphine include implant-site pain, itching, and redness, as well as headache, depression, constipation, nausea, vomiting, back pain, toothache and oropharyngeal pain. The safety and efficacy of Probuphine have not been established in children or adolescents less than 16 years of age. Clinical studies of Probuphine did not include participants over the age of 65.

Probuphine has a boxed warning that provides important safety information for health care professionals, including a warning that insertion and removal of Probuphine are associated with the risk of implant migration, protrusion, expulsion and nerve damage resulting from the procedure. Probuphine must be prescribed and dispensed according to the Probuphine REMS program because of the risks of surgical complications and because of the risks of accidental overdose, misuse and abuse if an implant comes out or protrudes from the skin. As part of this program, Probuphine can only be prescribed and dispensed by health care providers who are certified with the REMS program and have completed live training, among other requirements.

Probuphine implants contain a significant amount of drug that can potentially be expelled or removed, resulting in the potential for accidental exposure or intentional misuse and abuse if the implant comes out of the skin. Patients should be seen during the first week after insertion and a visit schedule of no less than once-monthly is recommended for continued counseling and psychosocial support.

Probuphine is marketed by San Francisco-based Titan Pharmaceuticals Inc. and Braeburn Pharmaceuticals based in Princeton, New Jersey.

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.




1 Initial small dose finding study
2 & 3 Two well-controlled Phase 3 safety and efficacy studies showing clinical and statistical superiority over placebo and non-inferiority to Suboxone published in Journal of American Medical Association and Addiction
4 & 5 Two open-label long-term treatment safety studies
6 Relative bioavailability study

  • Mild-to-moderate adverse events typical of the safety profile of buprenorphine; low number of serious adverse events similar to placebo
    Well-tolerated implant procedure
    No evidence of implant diversion or misuse



Effective in reducing illicit opioid use


Treatment with the ProNeura™ implant is expected to enhance patient compliance


Non-fluctuating drug exposure over six months may provide superior safety and tolerability


Patients are dosed once every six months in an outpatient setting



Titan's proprietary long-term, drug delivery platform provides continuous drug release and non-fluctuating medication levels over a period of three months to a year depending on drug characteristics. ProNeura products are subdermal implants that are ideal for treating chronic diseases for which the maintenance of stable medication levels could offer advantages over other routes of administration.


    ProNeura offers continuous drug delivery and consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (“EVA”) and a drug substance.                                                     .   The resulting product is a solid matrix that is placed subcutaneously, normally in the inner part of the upper arm in a simple office procedure, and is 
    removed in a similar manner at the end of the treatment period.

    This continuous drug delivery technology was developed to address the need for a simple, practical method to potentially provide continuous drug administration on an 
    outpatient basis over extended periods of up to 6 to 12 months.






Continuous Drug Delivery Technology



The continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (“EVA”) and a drug substance. The resulting product is a solid matrix that is placed subcutaneously, normally in the inner part of the upper arm in a simple office procedure, and is removed in a similar manner at the end of the treatment period. The drug substance is released slowly, at continuous levels, through the process of dissolution. This results in a stable blood level similar to intravenous administration. Such long-term, linear release characteristics are generally desirable as this avoids peak and trough level dosing that poses problems for many Central Nervous System (“CNS”) and other disease settings. 

This continuous drug delivery technology was developed to address the need for a simple, practical method to potentially provide continuous drug administration on an outpatient basis over extended periods of up to 6-12 months. In addition to Probuphine, which is the first product to complete clinical testing that has utilized this proprietary continuous drug delivery technology, Titan has conducted initial non-clinical studies with long-term delivery of dopamine agonists demonstrating the potential of this product in the treatment of Parkinson’s disease in non-clinical models of the disease.



Company Overview


Titan Pharmaceuticals, Inc. is a biopharmaceutical Company developing proprietary therapeutics primarily for the treatment of serious medical disorders.

Titan’s principal asset is Probuphine®, the first slow-release implant formulation of buprenorphine hydrochloride (“buprenorphine”), designed to maintain a stable, round-the-clock blood level of the medicine in patients for up to six months following a single treatment. The outpatient treatment of opioid dependence with daily dosed sublingual buprenorphine formulations represents a $1.5 billion market in the U.S., and a seven day transdermal patch formulation of buprenorphine for the treatment of chronic pain was launched in the U.S. in 2011. This novel implant formulation is inserted subdermally in a patient’s upper arm providing continuous medication, and has the potential to enhance patient compliance to treatment, and limit diversion for illicit use and accidental exposure to the sublingual formulations. An FDA-requested Phase 3 study is currently in progress with completion expected in mid-2015 and resubmission of the New Drug Application later in 2015. In December 2012, Titan entered into a license agreement with Braeburn Pharmaceuticals Sprl (“Braeburn”) that grants Braeburn exclusive commercialization rights to Probuphine® in the United States and Canada. Titan received a non-refundable up-front license fee of $15.75 million and will receive a $15 million milestone payment upon the approval of the NDA by the FDA. Additionally, Titan will be eligible to receive up to $165 million upon achievement of specified sales milestones and up to $35 million in regulatory milestones in the event of future NDA submissions and approvals for additional indications, including chronic pain. Titan will receive tiered royalties on net sales of Probuphine ranging from the mid-teens to the low twenties.

Probuphine is the first product to utilize ProNeura™, a novel, proprietary, long-term drug delivery technology. The ProNeura technology has the potential to be used in developing products for the treatment of other chronic conditions, such as Parkinson’s disease, where maintaining stable, round-the-clock blood levels of a drug can benefit the patient and improve medical outcomes.

Finally, Titan has monetized substantially all of the future royalty revenue of 8-10% of net sales of Fanapt® (iloperidone), an atypical antipsychotic compound being marketed in the U.S. for the treatment of schizophrenia by Novartis Pharma AG (“Novartis”). The future royalty revenue has been sold to Deerfield Management (“Deerfield”), a healthcare investment fund, in exchange for cash and debt considerations which have been used to advance the development of Probuphine and for general corporate purposes.



Management Team

Sunil Bhonsle, M.B.A.

Executive Vice President and Chief Development Officer

Katherine L. Beebe, Ph.D.

Executive Chairman

Marc Rubin, M.D.


Board of Directors

Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
#12321  Sticky Note Titan Pharmaceuticals and Opiant Pharmaceuticals Collaborate to Explore TRUTH 10/02/17 07:48:42 AM
#12416   I did listen to the broadcast..way too long Serenity3 10/23/17 02:00:00 PM
#12415   At White House opioid commission meeting, insurance industry Doctor Detroit 10/23/17 11:44:11 AM
#12414   Hypothyroidism by far is TTNP's largest potential market...from Doctor Detroit 10/23/17 10:06:35 AM
#12413   It will be interesting to see if sales Doctor Detroit 10/23/17 09:55:40 AM
#12412   Thanks Truth! Great News Doctor Detroit 10/23/17 09:54:32 AM
#12411   So apparently someone running a rehab center without Doctor Detroit 10/23/17 09:54:08 AM
#12410   Don't think it negative towards probuphine,but I think turks 10/22/17 04:44:25 PM
#12409   Article Tainting the Implant onlyimho 10/22/17 03:34:48 PM
#12408   Doc good article turks 10/21/17 02:51:20 PM
#12407   Truth absolutely right,like you said in the *beginning......they turks 10/20/17 09:33:14 AM
#12406   Manchester,NH, one of the many epicenters of opioid rikshot 10/19/17 08:29:54 PM
#12404   Hello Doc.... TRUTH 10/19/17 07:15:53 PM
#12403   Long-acting medications for opioid addiction help patients control Doctor Detroit 10/19/17 12:04:03 PM
#12402   Yes, he's very positive on Titan, but I Doctor Detroit 10/19/17 12:03:30 PM
#12401   Doc, Zacks analyst discussing about two companies and turks 10/18/17 02:59:50 PM
#12400   I totally agree with you guys,we shall see..thanks turks 10/17/17 11:28:36 PM
#12399   will have to wait & see how the Serenity3 10/17/17 11:20:43 PM
#12398   Thanks Doc.... turks 10/17/17 06:44:41 PM
#12397   It depends on whether Trump follows what the Doctor Detroit 10/17/17 06:18:34 PM
#12396   Doc,this is great news,it feels like a long turks 10/17/17 05:34:40 PM
#12395   National emergency declaration to come (finally) next week... Doctor Detroit 10/17/17 04:58:19 PM
#12394   Drug czar pick Tom Marino withdraws after opioid report rikshot 10/17/17 02:10:36 PM
#12393   Doc,I guess we know now where the money turks 10/16/17 10:11:32 PM
#12392   All this negative news ETC.towards LARGE PHARMA'S THAT turks 10/16/17 07:44:08 PM
#12391   Latest Gov't action on opioid addiction rikshot 10/16/17 03:17:36 PM
#12390   Ex-DEA agent: Opioid crisis fueled by drug industry rikshot 10/16/17 12:56:17 PM
#12389   After the 60 minute piece on addiction,titan should turks 10/16/17 11:36:49 AM
#12387   This was in titans website,very interesting news that turks 10/14/17 11:49:35 PM
#12386   60 Minutes to run piece on opioid epidemic turks 10/14/17 05:19:11 PM
#12385 turks 10/13/17 09:20:20 AM
#12384   agree.. but any price, royalty or buy out, Serenity3 10/12/17 08:07:00 PM
#12383   I would think the most attractive things about Doctor Detroit 10/12/17 07:01:50 PM
#12382   while not a conflict, there are downsides to Serenity3 10/12/17 03:46:47 PM
#12381   I don't see any conflict. Business is Doctor Detroit 10/12/17 02:39:54 PM
#12380   Indivior would be ideal,but wouldn't there be a turks 10/12/17 01:51:03 PM
#12379   Probably whoever offers the best deal, provided they Doctor Detroit 10/12/17 11:57:37 AM
#12378   So Doc which top three would you pick turks 10/12/17 08:29:16 AM
#12376   Hope your right,*if they learned or realize there turks 10/10/17 09:43:33 PM
#12375   My guess is they will learn their lesson Doctor Detroit 10/10/17 03:39:03 PM
#12374   Hope your right Doc partner wise,because according to turks 10/10/17 02:26:26 PM
#12373   Thanks! Doctor Detroit 10/10/17 11:03:37 AM
#12372 turks 10/10/17 09:33:32 AM
#12371   I worked @ a 6 month residential substance Serenity3 10/10/17 12:16:06 AM
#12370   Just another .35 and we'll be back at Rentier 10/09/17 06:39:34 PM
#12369   Born Addicted: The Number of Opioid-Addicted Babies Is Soaring rikshot 10/09/17 12:46:31 PM
#12368   Good point...the "partner" will be more of distributor Doctor Detroit 10/09/17 12:44:57 PM
#12367   EU may be 1/10 the market for opiate Serenity3 10/09/17 12:19:50 PM
#12366   Your trading program support software like "Java" or rikshot 10/09/17 11:09:49 AM